IS RUSSIA READY FOR THE INTRODUCTION OF THE NATIONAL REFERENCE PRICING SYSTEM?
Abstract
the analysis of foreign pricing and drug supply public funding systems (or a so-called drug reimbursement) shows a substantial variety and presence of national peculiarities; however the majority of the developed foreign countries apply reference pricing. As part of the introduction of reference pricing, internal and external price regulation can be distinguished. External referencing system has been used in Russia for several years already, while national or internal reference pricing system hasn’t been applied until recently. The introduction of the notion of interchangeability of drugs at the legislative level creates the preconditions for a deeper study of advantages and disadvantages of this system, as well as the possibility of its use in the Russian Federation. This article describes various options for the introduction of this system, its advantages and limitations.
About the Author
V. V. Omelyanovskiy
Russian Presidential Academy of National Economy and Public Administration, Federal State Educational Institution of Higher Professional Education, Moscow
Research Financial Institution of the Ministry of Finance of the Russian Federation, Federal State Budget Institution, Moscow
Russian Federation
Russian Federation
References
1. Adamyan N.V., Bazhenova A.V. Otsenka i vybor. 2011; 3: 39-43.
2. Changes from 22.12.2014 N 429-FZ of the law «On Circulation of Medicines» N 61-FZ [Izmeneniya ot 22.12.2014 N 429-FZ v zakon «Ob obrashchenii lekarstvennykh sredstv» N 61-FZ].
3. Omel'yanovskii V.V., Fedyaeva V.K., Rebrova O.Yu. Guidelines on the application of multi-criteria analysis in health care. Expert Health Council of the Federation Council Committee on Social Policy. Research Institute of Finance Ministry of Finance [Metodicheskie rekomendatsii po primeneniyu mnogokriterial'nogo analiza v zdravookhranenii. Ekspertnyi sovet po zdravookhraneniyu Komiteta Soveta Federatsii po sotsial'noi politike. Nauchno-issledovatel'skii finansovyi institut Ministerstva finansov RF. 2014].
4. Fedyaev D.V., Maksimova L.V., Omel'yanovskii V.V. Otsenka i vybor. 2014; 1: 57-64.
5. Diaby V., Campbell K., Goeree R. Multi-criteria decision analysis (MCDA) in health care: a bibliometric analysis. Operations Research for Health Care. 2013; 2 (1): 20-24.
6. Drummond M., Jönsson B., Rutten F., Stargardt T. Reimbursement of pharmaceuticals: reference pricing versus health technology assessment. Eur. J. Health Econ. 2011; 12 (3): 263-71.
7. Dylst P., Vulto A, Simoens S. Reference pricing systems in Europe: characteristics and consequence. Generics and Biosimilars Initiative Journal. 2012;1:127-31.
8. Dylst P., Vulto A., Simoens S. The impact of reference-pricing systems in Europe: a literature review and case studies. Expert Rev. Pharmacoecon. Outcomes Res. 2011; 11: 729-37.
9. European Generic medicines Association. 2011 Market Review. Brussels, Belgium: European Generic medicines Association. 2011.
10. Federal Joint Comittee. Reference prices and how they are set [Internet]. Fed. Jt. Com. Ger. [cited 2014 Oct 15].
11. Folino-Gallo P., Muscolo L., Vogler S., Morak S. PHIS Glossary: Glossary for pharmaceutical policies/systems developed in the Pharmaceutical Health Information System (PHIS) Project 2011. issued 2009, updated 2010 and 2011; Commissioned by the Executive Agency for Health and Consumers and the Austrian Federal Ministry of Health in the framework of the Pharmaceutical Health Information System Project. Available from: http://whocc.goeg.at/Publications/ Methodology.
12. Huttin C. Chapter 8: Experiences with reference pricing. Drugs Money – Prices Affordabil. Cost Contain. Part II Sel. Exp. Policy Options [Internet]. World Health Organization. 2003 [cited 2014 Oct 20]. Available from: http://apps.who.int/medicinedocs/en/d/ Js4912e/3.3.html.
13. Kanavos P., Reinhardt U.. Reference pricing for drugs: is it compatible with U.S. health care? Health Aff. (Millwood). 2003; 22 (3): 16-30.
14. López i Casasnovas G., Jonsson B. Universitat Pompeu Fabra, Centre de Recerca en Economia i Salut. Reference pricing and pharmaceutical policy: perspectives on economics and innovation. Barcelona. 2001.
15. Vrijens F., Van de Voorde C., Farfan-Portet M-I., le Polain M., Lohest O. The reference price system and socio-economic differences in the use of cheap medicines. Brussels, Belgium: KCE; 2010. Report No.: 126A.
Review
For citations:
Omelyanovskiy V.V. IS RUSSIA READY FOR THE INTRODUCTION OF THE NATIONAL REFERENCE PRICING SYSTEM? FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2014;7(4):36-41. (In Russ.)
Views:
827
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 